dc.contributor.author | Simsek-Duran, Fatma | |
dc.contributor.author | Ertunc, Mert | |
dc.contributor.author | Onur, Rustu | |
dc.date.accessioned | 2019-12-12T06:26:17Z | |
dc.date.available | 2019-12-12T06:26:17Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 0253-7613 | |
dc.identifier.uri | https://doi.org/10.4103/0253-7613.58509 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812779/ | |
dc.identifier.uri | http://hdl.handle.net/11655/16369 | |
dc.description.abstract | Objectives: The objective of this study was to investigate the effects of pentoxifylline (PTX), a drug that is mainly used for indications related to tissue hypoxia, on hypoxia-induced inhibition of skeletal muscle contractility and neuromuscular transmission in mice. We hypothesized that chronic PTX treatment alters skeletal muscle contractility and hypoxia-induced dysfunction. Materials and Methods: Mice were treated with 50 mg/kg PTX or saline intraperitoneally for a week. Following ether anesthesia, diaphragm muscles were removed; isometric muscle contractions and action potentials were recorded. Time to reach neuromuscular blockade and the rate of recovery of muscle contractility were assessed during hypoxia and re-oxygenation. Results: The PTX group displayed 90% greater twitch amplitudes (P < 0.01). Hypoxia depressed twitch contractions and caused neuromuscular blockade in both groups. However, neuromuscular blockade occurred earlier in PTX-treated animals (P < 0.05). Muscle contractures developed during hypoxia were more pronounced in the PTX group (P < 0.05). Re-oxygenation reduced contracture and indirect muscle contractions resumed. The rate of recovery of contractions was faster (P < 0.05) and the amplitude of contractions was greater (P < 0.01) in the PTX group. PTX treatment increased amplitude (P < 0.05) and shortened action potential (P < 0.05) without altering resting membrane potential, excitation threshold, and neurotransmitter release. Conclusion: Chronic PTX treatment increases diaphragm contractility, but amplifies hypoxia-induced contractile dysfunction in mice. These results may implicate important clinical consequences for clinical usage of PTX in hypoxia-related conditions. | |
dc.language.iso | en | |
dc.relation.isversionof | 10.4103/0253-7613.58509 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | The Effects of Pentoxifylline on Skeletal Muscle Contractility and Neuromuscular Transmission During Hypoxia | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Indian Journal of Pharmacology | |
dc.contributor.department | Fizyoloji | |
dc.identifier.volume | 41 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 213 | |
dc.identifier.endpage | 217 | |
dc.description.index | PubMed | |
dc.description.index | WoS | |